Biogen Inc (BIIB) Stock Price, Quote & News

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 617 679 2000

Website: www.biogen.com

Address:

225 Binney Street, Cambridge, United States

The_Alpha_Male Feb. 10 at 10:00 PM

$BIIB Undervalued?

0 · Reply

erevnon Feb. 10 at 2:54 PM

Wedbush maintains Biogen $BIIB at Neutral and raises the price target from $178 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

OptionRunners Feb. 9 at 8:18 PM

$BIIB call buyer

0 · Reply

erevnon Feb. 9 at 6:03 PM

RBC Capital maintains Biogen $BIIB at Outperform and raises the price target from $217 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Feb. 9 at 3:49 PM

Wells Fargo maintains Biogen $BIIB at Equal-Weight and raises the price target from $190 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Feb. 9 at 2:44 PM

Wedbush maintains Biogen $BIIB at Neutral and raises the price target from $178 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

MichaelDV Feb. 9 at 1:52 PM

$BIIB defending base, downside pressure noticeably lighter

0 · Reply

mikesterz7 Feb. 9 at 1:22 PM

$BIIB Analyst price targets for BIIB are in the range of $190 to $215, implying a downside of about 6% to an upside of nearly 7% from the last close.

0 · Reply

MichaelDV Feb. 9 at 1:21 PM

$BIIB biotech stabilizing after volatility, asymmetry improves with volume confirm

0 · Reply

John_Wick1234 Feb. 9 at 12:25 PM

$BIIB Nice Double Bottom with good Volume.

0 · Reply

Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Feb 9, 2026, 6:49 AM EST - 1 day ago

Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise

Feb 6, 2026, 2:14 PM EST - 4 days ago

Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript

Feb 6, 2026, 8:59 AM EST - 4 days ago

Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide

Feb 6, 2026, 7:35 AM EST - 4 days ago

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.

Feb 6, 2026, 6:10 AM EST - 4 days ago

Biogen forecasts annual profit above estimates as Leqembi sales pick up

Feb 4, 2026, 7:30 AM EST - 6 days ago

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Jan 28, 2026, 7:30 AM EST - 13 days ago

Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Jan 25, 2026, 6:30 PM EST - 16 days ago

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

Jan 13, 2026, 8:48 AM EST - 4 weeks ago

Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy

Jan 12, 2026, 7:45 PM EST - 4 weeks ago

Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 11:05 AM EST - 4 weeks ago

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Jan 11, 2026, 2:00 PM EST - 4 weeks ago

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

STOK

Jan 5, 2026, 8:00 PM EST - 5 weeks ago

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

Dec 30, 2025, 8:57 AM EST - 6 weeks ago

Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge

Dec 22, 2025, 11:20 AM EST - 7 weeks ago

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Dec 9, 2025, 7:00 AM EST - 2 months ago

Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada

Dec 8, 2025, 6:30 PM EST - 2 months ago

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Dec 5, 2025, 9:00 AM EST - 2 months ago

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

STOK

Dec 5, 2025, 9:00 AM EST - 2 months ago

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Dec 3, 2025, 2:03 PM EST - 2 months ago

Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 4:40 PM EST - 2 months ago

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Dec 2, 2025, 3:43 PM EST - 2 months ago

Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 1, 2025, 7:30 AM EST - 2 months ago

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Dec 1, 2025, 7:30 AM EST - 2 months ago

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

STOK

Nov 27, 2025, 7:30 PM EST - 2 months ago

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan

Nov 25, 2025, 7:30 AM EST - 2 months ago

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Nov 24, 2025, 11:17 AM EST - 2 months ago

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?

Nov 24, 2025, 7:30 AM EST - 2 months ago

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Nov 24, 2025, 7:30 AM EST - 2 months ago

Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership

Nov 24, 2025, 7:25 AM EST - 2 months ago

Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.

NVO

Nov 21, 2025, 1:13 PM EST - 2 months ago

AI Stocks Are Taking a Beating. What to Buy Instead.

AKAM AMZN EXPE LLY

Nov 20, 2025, 7:30 AM EST - 2 months ago

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference

Nov 18, 2025, 8:25 AM EST - 3 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN GILD GSK JNJ LLY

Nov 17, 2025, 7:30 AM EST - 3 months ago

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Nov 17, 2025, 7:30 AM EST - 3 months ago

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

STOK

Nov 17, 2025, 6:00 AM EST - 3 months ago

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Nov 14, 2025, 4:05 PM EST - 3 months ago

Biogen Completes Acquisition of Alcyone Therapeutics

IONS

Nov 13, 2025, 6:41 PM EST - 3 months ago

Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript

Nov 13, 2025, 6:30 PM EST - 3 months ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Nov 10, 2025, 5:01 PM EST - 3 months ago

Biogen Inc. (BIIB) Presents at Wedbush Rewind ASN 2025 Conference Prepared Remarks Transcript

Nov 3, 2025, 7:30 AM EST - 3 months ago

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Oct 30, 2025, 9:16 PM EDT - 3 months ago

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:40 AM EDT - 3 months ago

Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise

Oct 30, 2025, 6:11 AM EDT - 3 months ago

Biogen trims annual profit forecast on expected hit from R&D-related charges

Oct 26, 2025, 7:30 PM EDT - 3 months ago

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease

Oct 24, 2025, 8:30 AM EDT - 3 months ago

Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion

Oct 24, 2025, 7:30 AM EDT - 3 months ago

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

Oct 22, 2025, 7:30 AM EDT - 3 months ago

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

Oct 13, 2025, 7:30 PM EDT - 4 months ago

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”

The_Alpha_Male Feb. 10 at 10:00 PM

$BIIB Undervalued?

0 · Reply

erevnon Feb. 10 at 2:54 PM

Wedbush maintains Biogen $BIIB at Neutral and raises the price target from $178 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

OptionRunners Feb. 9 at 8:18 PM

$BIIB call buyer

0 · Reply

erevnon Feb. 9 at 6:03 PM

RBC Capital maintains Biogen $BIIB at Outperform and raises the price target from $217 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Feb. 9 at 3:49 PM

Wells Fargo maintains Biogen $BIIB at Equal-Weight and raises the price target from $190 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Feb. 9 at 2:44 PM

Wedbush maintains Biogen $BIIB at Neutral and raises the price target from $178 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

MichaelDV Feb. 9 at 1:52 PM

$BIIB defending base, downside pressure noticeably lighter

0 · Reply

mikesterz7 Feb. 9 at 1:22 PM

$BIIB Analyst price targets for BIIB are in the range of $190 to $215, implying a downside of about 6% to an upside of nearly 7% from the last close.

0 · Reply

MichaelDV Feb. 9 at 1:21 PM

$BIIB biotech stabilizing after volatility, asymmetry improves with volume confirm

0 · Reply

John_Wick1234 Feb. 9 at 12:25 PM

$BIIB Nice Double Bottom with good Volume.

0 · Reply

erevnon Feb. 9 at 11:52 AM

Piper Sandler maintains Biogen $BIIB at Neutral and raises the price target from $157 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

anachartanalyst Feb. 9 at 11:01 AM

$BIIB https://anachart.com/wp-content/uploads/ana_temp/1770634874_soc-img.jpg

0 · Reply

StocktwitsNews Feb. 9 at 4:14 AM

Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi $BIIB https://stocktwits.com/news/equity/markets/biogen-stock-to-pop-again-china-fast-tracks-at-home-alzheimers-drug-leqembi/cZbHVi7R48i

0 · Reply

Whiskey1679 Feb. 8 at 11:19 PM

Whiskey's Penny Picks out early tomorrow morning! Movers & Shakers: $CHR.X $BIIB $ASTER.X $CC.X $JYAI.X

0 · Reply

mikesterz7 Feb. 8 at 10:59 PM

$BIIB Despite EPS guidance of $15.25–$16.25 for 2026, management expects total revenue to decline mid‑single digits and legacy MS revenues (ex‑Vumerity) to fall by mid‑teens % in 2026 due to generic and biosimilar pressure.

0 · Reply

FlamingPhoenix Feb. 8 at 10:38 PM

$BIIB

0 · Reply

DonCorleone77 Feb. 8 at 10:16 PM

$BIIB Biogen price target raised to $200 from $190 at Wells Fargo Wells Fargo raised the firm's price target on Biogen to $200 from $190 and keeps an Equal Weight rating on the shares post the Q4 report. The firm expects the company's 2026 launch execution to remain steady. Biogen's near-term late-stage catalysts can improve outlook toward the end of the decade, the analyst tells investors in a research note.

0 · Reply

DonCorleone77 Feb. 8 at 10:16 PM

$BIIB Biogen price target raised to $207 from $189 at BofA BofA raised the firm's price target on Biogen to $207 from $189 and keeps a Neutral rating on the shares post the Q4 report. The firm attributes the post-earnings share rally to "clear positives" from the call, including "not as bad as feared erosion" of the multiple sclerosis franchise, the analyst tells investors in a research note.

0 · Reply

DonCorleone77 Feb. 8 at 10:15 PM

$BIIB Biogen price target raised to $215 from $185 at Citi Citi analyst Geoff Meacham raised the firm's price target on Biogen to $215 from $185 and keeps a Neutral rating on the shares. The firm views the company's Q4 report as solid and remains optimistic on its ability to launch new products and develop its pipeline.

0 · Reply

DonCorleone77 Feb. 8 at 10:14 PM

$BIIB Biogen price target raised to $190 from $156 at Morgan Stanley Morgan Stanley analyst Terence Flynn raised the firm's price target on Biogen to $190 from $156 and keeps an Equal Weight rating on the shares. The firm sees the company's "building" pipeline as the focus post the Q4 report.

0 · Reply

Renee1957 Feb. 8 at 5:20 PM

$BIIB beautiful chart

0 · Reply

WallStreetBuyDip Feb. 7 at 11:32 PM

$BIIB Trading around $200, hit a high at $201.18. Looks like it's been climbing from lows around $113. Volume spiked to 3,404,300 on Feb 6.

0 · Reply

Market Cap	28.43B
Revenue (ttm)	9.89B
Net Income (ttm)	1.29B
EPS (ttm)	N/A
PE Ratio	13.16
Forward PE	13.56
Profit Margin	13.07%
Debt to Equity Ratio	0.34

Volume	1,836,100
Avg Vol	1,927,446
Day's Range	N/A - N/A
Shares Out	146.70M
Stochastic %K	54%
Beta	0.16
Analysts	Sell
Price Target	$195.86